herbalife ltd. - HLF
HLF
Close Chg Chg %
7.92 -0.16 -2.02%
Open Market
7.76
-0.16 (2.02%)
Volume: 574.68K
Last Updated:
Dec 3, 2024, 12:51 PM EDT
Company Overview: herbalife ltd. - HLF
HLF Key Data
Open $7.88 | Day Range 7.68 - 7.92 |
52 Week Range 6.59 - 15.66 | Market Cap $797.26M |
Shares Outstanding 100.79M | Public Float 97.91M |
Beta 1.17 | Rev. Per Employee N/A |
P/E Ratio 9.26 | EPS $0.86 |
Yield 0.00% | Dividend $0.30 |
EX-DIVIDEND DATE Feb 28, 2014 | SHORT INTEREST N/A |
AVERAGE VOLUME 2.27M |
HLF Performance
1 Week | 1.80% | ||
1 Month | 1.02% | ||
3 Months | 5.05% | ||
1 Year | -39.85% | ||
5 Years | -82.59% |
HLF Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
About herbalife ltd. - HLF
Herbalife Ltd. is a holding company, which engages in the provision of health and wellness products. It operates through the following geographical segments: North America, Latin America, EMEA, Asia Pacific, and China. The company was founded by Mark Reynolds Hughes in February 1980 and is headquartered in Los Angeles, CA.
HLF At a Glance
Herbalife Ltd.
800 West Olympic Boulevard
Los Angeles, California 90015
Phone | N/A | Revenue | 5.06B | |
Industry | Medical Distributors | Net Income | 142.20M | |
Sector | Distribution Services | Employees | 9,200 | |
Fiscal Year-end | 12 / 2024 | |||
View SEC Filings |
HLF Valuation
P/E Current | 9.262 |
P/E Ratio (with extraordinary items) | N/A |
P/E Ratio (without extraordinary items) | 10.753 |
Price to Sales Ratio | 0.302 |
Price to Book Ratio | N/A |
Price to Cash Flow Ratio | 4.277 |
Enterprise Value to EBITDA | 8.556 |
Enterprise Value to Sales | 0.732 |
Total Debt to Enterprise Value | 0.747 |
HLF Efficiency
Revenue/Employee | 550,260.87 |
Income Per Employee | 15,456.522 |
Receivables Turnover | 51.657 |
Total Asset Turnover | 1.827 |
HLF Liquidity
Current Ratio | 1.095 |
Quick Ratio | 0.70 |
Cash Ratio | 0.462 |
HLF Profitability
Gross Margin | 74.68 |
Operating Margin | 6.323 |
Pretax Margin | 4.01 |
Net Margin | 2.809 |
Return on Assets | 5.132 |
Return on Equity | N/A |
Return on Total Capital | 8.32 |
Return on Invested Capital | 9.643 |
HLF Capital Structure
Total Debt to Total Equity | N/A |
Total Debt to Total Capital | 162.035 |
Total Debt to Total Assets | 98.58 |
Long-Term Debt to Equity | N/A |
Long-Term Debt to Total Capital | 141.616 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Herbalife Ltd. - HLF
Collapse All in section
All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
---|---|---|---|---|---|
Sales/Revenue
| 5.54B | 5.80B | 5.20B | 5.06B | |
Sales Growth
| +13.63% | +4.71% | -10.31% | -2.73% | |
Cost of Goods Sold (COGS) incl D&A
| 1.23B | 1.32B | 1.26B | 1.28B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 100.30M | 107.60M | 115.40M | 113.30M | |
Depreciation
| 80.90M | 89.20M | 94.30M | 88.90M | |
Amortization of Intangibles
| 19.40M | 18.40M | 21.10M | 24.40M | |
COGS Growth
| +19.36% | +7.31% | -5.06% | +2.02% | |
Gross Income
| 4.31B | 4.48B | 3.95B | 3.78B | |
Gross Income Growth
| +12.09% | +3.97% | -11.86% | -4.24% | |
Gross Profit Margin
| +77.75% | +77.19% | +75.86% | +74.68% |
2020 | 2021 | 2022 | 2023 | 5-year trend | |
---|---|---|---|---|---|
SG&A Expense
| 3.56B | 3.75B | 3.41B | 3.46B | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 3.56B | 3.75B | 3.41B | 3.46B | |
SGA Growth
| +7.60% | +5.19% | -8.98% | +1.42% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 123.70M | 36.00M | (500.00K) | (1.60M) | |
EBIT after Unusual Expense
| 621.20M | 694.80M | 536.60M | 321.70M | |
Non Operating Income/Expense
| 27.70M | 18.20M | 27.70M | 47.20M | |
Non-Operating Interest Income
| 8.80M | 4.40M | 6.10M | 11.50M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 132.50M | 152.20M | 139.50M | 166.20M | |
Interest Expense Growth
| -13.40% | +14.87% | -8.34% | +19.14% | |
Gross Interest Expense
| 132.50M | 152.20M | 139.50M | 166.20M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 516.40M | 560.80M | 424.80M | 203.00M | |
Pretax Income Growth
| +14.40% | +8.60% | -24.25% | -52.21% | |
Pretax Margin
| +9.32% | +9.66% | +8.16% | +4.01% | |
Income Tax
| 143.80M | 113.60M | 103.50M | 60.80M | |
Income Tax - Current - Domestic
| 19.80M | 25.10M | 33.30M | 21.10M | |
Income Tax - Current - Foreign
| 122.00M | 121.80M | 100.10M | 80.80M | |
Income Tax - Deferred - Domestic
| 4.70M | (16.30M) | (27.90M) | (39.40M) | |
Income Tax - Deferred - Foreign
| (2.70M) | (17.00M) | (2.00M) | (1.70M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 372.60M | 447.20M | 321.30M | 142.20M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 372.60M | 447.20M | 321.30M | 142.20M | |
Net Income Growth
| +19.81% | +20.02% | -28.15% | -55.74% | |
Net Margin Growth
| +6.72% | +7.71% | +6.17% | +2.81% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 372.60M | 447.20M | 321.30M | 142.20M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 372.60M | 447.20M | 321.30M | 142.20M | |
EPS (Basic)
| 2.8335 | 4.2228 | 3.2619 | 1.4364 | |
EPS (Basic) Growth
| +25.18% | +49.03% | -22.76% | -55.96% | |
Basic Shares Outstanding
| 131.50M | 105.90M | 98.50M | 99.00M | |
EPS (Diluted)
| 2.7703 | 4.1293 | 3.2292 | 1.4192 | |
EPS (Diluted) Growth
| +26.13% | +49.06% | -21.80% | -56.05% | |
Diluted Shares Outstanding
| 134.50M | 108.30M | 99.50M | 100.20M | |
EBITDA
| 845.20M | 838.40M | 651.50M | 433.40M | |
EBITDA Growth
| +34.24% | -0.80% | -22.29% | -33.48% | |
EBITDA Margin
| +15.25% | +14.45% | +12.52% | +8.56% |
Snapshot
Average Recommendation | HOLD | Average Target Price | 11.80 | |
Number of Ratings | 7 | Current Quarters Estimate | 0.132 | |
FY Report Date | 12 / 2024 | Current Year's Estimate | 1.733 | |
Last Quarter’s Earnings | 0.57 | Median PE on CY Estimate | N/A | |
Year Ago Earnings | 2.21 | Next Fiscal Year Estimate | 2.023 | |
Median PE on Next FY Estimate | N/A |
Earnings Per Share
This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
---|---|---|---|---|
# of Estimates | 5 | 4 | 5 | 5 |
Mean Estimate | 0.13 | 0.43 | 1.73 | 2.02 |
High Estimates | 0.25 | 0.48 | 1.85 | 2.19 |
Low Estimate | -0.10 | 0.37 | 1.51 | 1.83 |
Coefficient of Variance | 107.64 | 13.74 | 7.92 | 7.28 |
Analysts Recommendations
Current | 1 Month Ago | 3 Months Ago | |
---|---|---|---|
BUY | 2 | 2 | 2 |
OVERWEIGHT | 0 | 0 | 0 |
HOLD | 4 | 4 | 4 |
UNDERWEIGHT | 1 | 1 | 1 |
SELL | 0 | 0 | 0 |
MEAN | Hold | Hold | Hold |
SEC Filings for Herbalife Ltd. - HLF
Filing Date | Type | Category | Amended |
---|---|---|---|
No results |
Insider Actions for Herbalife Ltd. - HLF
Date | Name | Shares | Transaction | Value |
---|---|---|---|---|
May 13, 2024 | Juan Miguel Mendoza Director | 80,779 | Open market or private purchase of non-derivative security Non-derivative transaction at $10.17 per share | 821,522.43 |
May 13, 2024 | Juan Miguel Mendoza Director | 86,279 | Open market or private purchase of non-derivative security Non-derivative transaction at $10.59 per share | 913,694.61 |
May 13, 2024 | Juan Miguel Mendoza Director | 93,279 | Open market or private purchase of non-derivative security Non-derivative transaction at $10.65 per share | 993,421.35 |
May 8, 2024 | Alan W. LeFevre Director | 69,117 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | Jehangir D. Irani SVP, PAO | 66,573 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $9.58 per share | 637,769.34 |
May 8, 2024 | Sophie L'Hélias Director | 43,746 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | Frank Lamberti Chief Operating Officer | 212,550 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | Frank Lamberti Chief Operating Officer | 248,838 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $9.58 per share | 2,383,868.04 |
May 8, 2024 | Frank Lamberti Chief Operating Officer | 250,857 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | Ibelis Inglewood Fleming EVP & Chief of Staff | 151,821 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | Ibelis Inglewood Fleming EVP & Chief of Staff | 160,812 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $9.58 per share | 1,540,578.96 |
May 8, 2024 | Ibelis Inglewood Fleming EVP & Chief of Staff | 162,831 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | Michael Jeffrey Levitt Director | 15,657 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | Rodica Macadrai Director | 33,705 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | Celine Del Genes Director | 33,961 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | Richard H. Carmona Director | 49,909 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | María Otero Director | 58,193 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | Henry C. Wang EVP, General Counsel | 212,550 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | Henry C. Wang EVP, General Counsel | 213,673 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
May 8, 2024 | Henry C. Wang EVP, General Counsel | 209,325 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $9.58 per share | 2,005,333.50 |